




Supplementary Material

Efficacy of Danshen (*Salvia miltiorrhiza*) Dripping Pills for Prevention of Acute Mountain Sickness: A Randomized, Double-Blind, Placebo-Controlled Trial

Kui Li¹, Lijun Li¹, Jialun Fu², Yi He², Zhaohui Song², Shuiping Zhou², Luobu Gesang^{1*} and Rui Liu^{2*}


¹Tibet Autonomous Region People's Hospital, Tibet, China

²Tasly Pharmaceutical Group Company Limited, Tianjin, China




Supplementary Fig. S1. SaO₂ for subjects taking CDDPs or placebos at each time point. The asterisk indicates $p < 0.05$ between the treatment and CON groups at that observation time.

* Corresponding author: dr.licorrespond@gmail.com;
dr.licorrespond@gmail.com
0030-9923/2020/0006-2215 \$ 9.00/0
Copyright 2020 Zoological Society of Pakistan



Supplementary Fig. S2. Heart rates of subjects taking CDDPs or placebos at each time point. The asterisk indicates $p < 0.05$ between the treatment and CON groups at that observation time.



Supplementary Fig. S3. Blood pressures of subjects taking CDDPs or the placebo at each time point. (a) Systolic blood pressure (mmHg). (b) Diastolic blood pressure (mmHg). Asterisks indicate $p < 0.05$ between the treatment and CON groups at that observation time.

Supplementary Table S1. Kaplan-Meier estimation of the AMS incidence at each time point.

Item	Treatment group (N = 29)	CON group (N = 29)
Incidence time (d) (Log-Rank test=0.00, P = 0.9479)		
1	0.00(.,.)	0.00(.,.)
2	0.00(.,.)	3.45(0.49,22.05)
3	13.79(5.41,32.69)	17.24(7.57,36.57)
4	24.14(12.31,44.06)	20.69(9.87,40.36)
5	24.14(12.31,44.06)	27.59(14.87,47.66)
6	24.14(12.31,44.06)	27.59(14.87,47.66)
7	24.14(12.31,44.06)	27.59(14.87,47.66)
8	27.59(14.87,47.66)	27.59(14.87,47.66)
25% survival (95%CI)	8.00(3.00,.)	5.00(3.00,.)
50% survival (95%CI)	.(.,.)	.(.,.)
75% survival (95%CI)	.(.,.)	.(.,.)
Censoring rate (%)	72.41	72.41